Factor VIII inhibitor bypassing fraction - Shire

Drug Profile

Factor VIII inhibitor bypassing fraction - Shire

Alternative Names: Anti-inibitor coagulant complex - Shire; Feiba

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Baxter Healthcare Corporation
  • Developer Shire
  • Class Antihaemorrhagics; Coagulants
  • Mechanism of Action Blood coagulation factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemophilia; Haemophilia A; Haemophilia B

Most Recent Events

  • 03 Jun 2016 Baxalta has been acquired and merged into Shire
  • 19 Dec 2013 Registered for Haemophilia A (prevention) in USA (IV)
  • 19 Dec 2013 Final adverse events and efficacy data from the phase III FEIBA PROOF trial in Haemophilia A and B (prevention) released by Baxter Healthcare
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top